Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels

American Journal of Hematology

Volumn 74, Issue 2, 2003, Pages 104-111

  Eberhardt, Robert T ^a,b,d   McMahon, Lillian ^a,b   Duffy, Stephen J ^c   Steinberg, Martin H ^a,b   Perrine, Susan P ^a,b   Loscalzo, Joseph ^a   Coffman, Jay D ^a   Vita, Joseph A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston Compreh Sickle Cell Center   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endothelium; L arginine; Nitric oxide; Sickle cell anemia; Vascular function; Vitamin C

Indexed keywords

ANTIOXIDANT; ARGININE; ASCORBIC ACID; GLYCERYL TRINITRATE; HEMOGLOBIN A; HEMOGLOBIN S; METHACHOLINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOTHELIUM CELL; FEMALE; FLOW KINETICS; FOREARM BLOOD FLOW; HUMAN; MALE; OXIDATION KINETICS; OXIDATIVE STRESS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE BLOOD VESSEL; SICKLE CELL ANEMIA; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; ANEMIA, SICKLE CELL; BLOOD VESSELS; BRACHIAL ARTERY; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; FOREARM; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; METHACHOLINE CHLORIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 0141730299     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10387     Document Type: Article

References (23)

1. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-1030.
2. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;100(11 Suppl):S83-S86.
3. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
4. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001;98:15215-15220.
5. Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 2000;279:R1949-R1955.
6. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 2000;278:H1799-H1806.
7. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001;97:1584-1589.
8. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389.
9. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271-278.
10. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 2000;35:936-941.
11. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-1113.
12. Gokce N, Keaney JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-3240.
13. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 1995;25:1402-1407.
14. Katz SD, Krum H. Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol 2001;87:1089-1092.
15. Platt JL, Nath KA. Heme oxygenase: protective gene or Trojan horse. Nat Med 1998;4:1364-1365.
16. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 1982;70:1253-1259.
17. Klings ES, Christman BW, McClung J, et al. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med 2001;164:1248-1252.
18. Huang A, Vita JA, Venema RC, Keaney JF xJr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intra-cellular tetrahydrobiopterin. J Biol Chem 2000;275:17399-17406.
19. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Ped Hem Onc 2000;22:515-520.
20. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-2157.
21. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haem 2000;111:498-500.
22. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
23. French JA, Kenny D, Scott JP, et al. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 1997;89:4591-4599.